bioimarkers can be described as measurable and quantifiable
biological indicators of normal physiological function, disease
states, or of the body's response to therapeutics.
Biomarkers are present in bodily fluids, such as blood
and blood fractions (plasma, serum etc), urine, saliva
and tissues.
Biomarkers, while often considered to only be proteins, can also take the
form of a specific measurement such as an ECG or imaging test (E.g. MRI or
CT scan) or can be a physical assessment or verbal test
The Biomarkers Definitions Working Group (2001) classified the
different types of biomarker based on function
Biomarkers can be
Diagnostic
Prognostic
Predictive
Staging
Surrogate endpoints
Diagnostic Biomarkers
function:
diagnostic tool for identification of patients
with a disease or abnormal condition
e.g. elevated blood glucose in individuals with diabetes mellitus
widely used in diagnosis of cancer
have the ability to determine the primary
tumour in cases where it has metastasised
Prognostic Biomarkers
Prognosis refers to the natural course of
the disease in the absence of treatment
takes place after an individual has been
diagnosed with cancer
Clinical example
breast cancer
better prognosis in patients that are ER+/PR+/HER+
poor prognosis for cancers negative for these receptors
Some cancers more aggressive than others
biomarkers can help distinguish between
rapidly growing and slowly growing cancers
patients can then receive different treatment
patients with slowly growing tumours
may be spared aggressive treatments
Predictive Biomarkers
give an indication as to the
likely response to treatment
likelihood of developing a disease
likelihood of disease recurrence
clinical importance:
some cancers that affect the same part of the body may
exhibit differences from person to person
can influence how they respond to treatment
EXAMPLE
Human Epidermal Growth Factor Receptor 2 gene (HER2)
1/4 of breast cancer patients have a mutation in HER2 gene
causes overexpression of HER2
HER2+ breast cancers are likely to respond to
Trastuzimab, which inhibits HER2 protein activity
HER2- patients will not respond to Trastuzimab
and so are not given this therapy
HER2 overexpression causes breast cancers
to rapidly grow and divide
aggressive cancer
HER2 us a prognostic AND predictive biomarker
OncotypeDX is used in early stage ER+ patients
who will be treated with hormone therapy
evaluates a panel of 21 genes from a
tumour biopsy sample
results in the form of a recurrence score indicating
the likelhood of tumour recurring in the next 10 years
Staging Biomarkers
used as a tool to classify the extent or stage of the disease
Example
CA-125 elevation in ovarian cancer
PSA concentration in blood
reflects extent of tumour growth and
metastasis in prostate cancer
Surrogate endpoints
clincal endpoint is a characteristic or variable that
reflects how a patient feels, functions or survives
they are distinct measurements of disease characteristics
observed in a study that reflect the effect of therapeutic
intervention
A surrogate endpoint is a biomarker that is intended
to substitute for a clinical endpoint
it is expected to predict clinical benefit based on
epidaemiologic, therapeutic, pathophysiologic or other
scientific evidence
EXAMPLE:
effect of drug therapy on cancer progression and survival
use of a validated surrogate endpoint would prevent patients
having to undergo tumour biopsies and trials to see if a drug
worked
Instead, a blood test could be performed to determine whetehr the
biomarker has increased or decreased in response to the drug